"The work of Feldmann and Maini has dramatically transformed the treatment of chronic inflammatory conditions and given millions of people new hope," said Paul Stoffels, M.D., Company Group Chairman, Research & Development, Pharmaceuticals, Johnson & Johnson. "The passion with which these two scientists have driven forward translational research reflects the leadership and innovation that defined Dr. Paul. Johnson & Johnson is delighted to honor them with the Dr. Paul Janssen Award for Biomedical Research."
Harlan Weisman, M.D., Chief Science and Technology Officer, Medical Devices and Diagnostics, Johnson & Johnson, concurred. "Scientific breakthroughs that have the power to transform an entire field of medicine, such as the discovery of TNF-alpha's role as a therapeutic target, are rare and game-changing. Feldman and Maini's work has tremendous potential to transform research and human health, and it has shed new light on how we study crippling immune mediated inflammatory disorders."
In addition to winning the 2008 Dr. Paul Janssen Award for Biomedical Research, Feldmann and Maini have been widely honored for their work. They received the Albert Lasker Clinical Medical Research Award in 2003 and the Crafoord Prize of the Royal Swedish Academy in 2000, among others.
About the Selection Committee
The Dr. Paul Janssen Award for Biomedical Research independent
selection committee is composed of some of the world's leading scientists,
including National Medal of Science winners, Nobel Laureates, members of
the National Academy of Sciences, and past winners of the Dr. Paul Janssen
Award for Biomedical Research. The 2008 selection committee includes:
-- Solomon Snyder, Ph.D., (chairman) Distinguished Service Professor of
Neuroscience, Pharmacology and Psychiatry, Johns Hopkins School of
|SOURCE Johnson & Johnson Pharmaceutical Research & Development,L.L.C.|
Copyright©2008 PR Newswire.
All rights reserved